Roche Reports Five-Year GALLIUM Data for Gazyva in Follicular Lymphoma

Roche today presented five-year follow-up data from the Phase 3 GALLIUM trial evaluating Gazyva (obinutuzumab) plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated advanced follicular lymphoma. The data showed that the progression-free survival benefit of Gazyva was maintained at five years, with a 34% reduction in the risk of disease progression or death.